<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37018046</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2576-9456</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>The journal of applied laboratory medicine</Title><ISOAbbreviation>J Appl Lab Med</ISOAbbreviation></Journal><ArticleTitle>Diagnostic Performance of Anti-dsDNA Tests by Indirect Immunofluorescence and Enzyme-linked Immunosorbent Assay in Patients with Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>713</StartPage><EndPage>725</EndPage><MedlinePgn>713-725</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jalm/jfad006</ELocationID><Abstract><AbstractText Label="BACKGROUND">Several laboratory techniques for anti double-stranded (ds) DNA detection in systemic lupus erythematosus (SLE) are available, with variable diagnostic performance. We aimed to evaluate anti-dsDNA's diagnostic performance by indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (EIA).</AbstractText><AbstractText Label="METHODS">We conducted a single-center retrospective (2015 to 2020) study. Patients with anti-dsDNA tests by IIF and EIA were included. We evaluated the indications, applications, concordance, positive predictive value (PPV) of anti-dsDNA to confirm SLE diagnosis or flares, and associations of disease manifestations with positivity with each technique.</AbstractText><AbstractText Label="RESULTS">A total of 1368 reports of anti-dsDNA tests by IIF and EIA and the corresponding medical records of the patients were analyzed. The main indication for anti-dsDNA testing was to help in the diagnosis of SLE in 890 (65%) of the samples, and the main application after obtaining the results was SLE exclusion in 782 (57.2%) cases. The combination with the highest frequency was the negativity result by both techniques in 801 (58.5%) cases (Cohen kappa 0.57). Both methods were positive in 300 patients with SLE (Cohen kappa 0.42). The PPVs of anti-dsDNA tests to confirm diagnosis/flare was 79.64% (95% CI, 75.35-83.35) by EIA, 78.75% (95% CI, 74.27-82.62) by IIF, and 82% (95% CI, 77.26-85.93) when both were positive.</AbstractText><AbstractText Label="CONCLUSIONS">Anti-dsDNA detection by IIF and EIA are complementary and may indicate different clinical patterns in patients with SLE. The detection of anti-dsDNA antibodies by both techniques has a higher PPV than either separately for confirming SLE diagnosis or flares. These results highlight the need for evaluating both methods in clinical practice.</AbstractText><CopyrightInformation>&#xa9; American Association for Clinical Chemistry 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nieto-Aristiz&#xe1;bal</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-1813-0674</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3;n Valle del Lili, Centro de Investigaciones Cl&#xed;nicas, Cra. 98 No. 18-49, Cali 760032, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espa&#xf1;a</LastName><ForeName>Laura Jackeline</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Universidad Icesi, Facultad de Ciencias de la Salud, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortega</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universidad Icesi, Facultad de Ciencias de la Salud, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Ordo&#xf1;ez</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Valle del Lili, Centro de Investigaciones Cl&#xed;nicas, Cra. 98 No. 18-49, Cali 760032, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vivas</LastName><ForeName>&#xc1;lvaro J</ForeName><Initials>&#xc1;J</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Valle del Lili, Centro de Investigaciones Cl&#xed;nicas, Cra. 98 No. 18-49, Cali 760032, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casta&#xf1;o</LastName><ForeName>Gloria L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Valle del Lili, Laboratorio Cl&#xed;nico, Cra. 98 No. 18-49, Cali 760032, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castillo</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3;n Valle del Lili, Laboratorio Cl&#xed;nico, Cra. 98 No. 18-49, Cali 760032, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bautista-Vargas</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universidad Icesi, Facultad de Ciencias de la Salud, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su&#xe1;rez</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universidad Icesi, Facultad de Ciencias de la Salud, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ca&#xf1;as</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Universidad Icesi, CIRAT: Centro de Investigaci&#xf3;n en Reumatolog&#xed;a, Autoinmunidad y Medicina Traslacional, Cali, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3;n Valle del Lili, Unidad de Reumatolog&#xed;a, Cra. 98 No. 18-49, Cali 760032, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tob&#xf3;n</LastName><ForeName>Gabriel J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0002-6031-4218</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3;n Valle del Lili, Centro de Investigaciones Cl&#xed;nicas, Cra. 98 No. 18-49, Cali 760032, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Microbiology, Immunology and Cell Biology, Southern Illinois University, Springfield, IL 62901, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Appl Lab Med</MedlineTA><NlmUniqueID>101693884</NlmUniqueID><ISSNLinking>2475-7241</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000718988">anti-dsDNA autoantibody</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019084" MajorTopicYN="N">Fluorescent Antibody Technique, Indirect</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="Y">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>5</Day><Hour>12</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37018046</ArticleId><ArticleId IdType="doi">10.1093/jalm/jfad006</ArticleId><ArticleId IdType="pii">7108360</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>